# LINZESS® (linaclotide) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/linaclotide

> LINZESS® (linaclotide), sponsored by AbbVie Inc. (ABBV): 9 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | LINZESS® (linaclotide) |
| Codes |  |
| Sponsor | AbbVie Inc. (ABBV) https://sec-api.dev/companies/abbv/catalysts |
| Indications | [functional constipation](https://sec-api.dev/indications/functional-constipation), Functional Constipation (FC) |
| Modality | peptide |
| FDA designations | priority review |

## Timeline

### September 22, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA202811 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20200922, review_priority STANDARD; sponsor_name ABBVIE; product LINZESS (LINACLOTIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202811%22

### June 12, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA202811 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20230612, review_priority PRIORITY; sponsor_name ABBVIE; product LINZESS (LINACLOTIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202811%22

### June 9, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Functional Constipation.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05760313 (A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-09 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-01-06." https://clinicaltrials.gov/study/NCT05760313

### September 2, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Functional Constipation (FC); Chronic Idiopathic Constipation (CIC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05652205 (A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-02 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-05-14." https://clinicaltrials.gov/study/NCT05652205

### November 4, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA202811 SUPPL-22 (Efficacy): submission_status AP, submission_status_date 20251104, review_priority PRIORITY; sponsor_name ABBVIE; product LINZESS (LINACLOTIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202811%22

### Jan 2026: NDA/BLA acceptance

- Status: completed. Date confidence: month. Indication: functional constipation.
- First seen 2026-05-07, last confirmed 2026-05-07.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-056656): "January 2026, the FDA accepted and granted priority review of a supplemental New Drug Application (sNDA) for LINZESS for the treatment of functional constipation (FC) in patients 2 to 5 years of age." https://www.sec.gov/Archives/edgar/data/1446847/000110465926056656/tm267094d1_ex99-1.htm

### January 6, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 2. Indication: Functional Constipation.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05760313 (A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-09 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-01-06." https://clinicaltrials.gov/study/NCT05760313?tab=results

### May 14, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Functional Constipation (FC); Chronic Idiopathic Constipation (CIC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05652205 (A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-02 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-05-14." https://clinicaltrials.gov/study/NCT05652205?tab=results

### May 21, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA202811 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20260521, review_priority PRIORITY; sponsor_name ABBVIE; product LINZESS (LINACLOTIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202811%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/linaclotide.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "LINZESS® (linaclotide) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/linaclotide

```bibtex
@misc{secapidev_pdufa_linaclotide_20261116,
  title        = {LINZESS® (linaclotide) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/linaclotide}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_linaclotide_20261116","title":"LINZESS® (linaclotide) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/linaclotide","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
